ライフサイエンスコーパス: D3 receptor

1 HT2B, 5-HT6, 5-HT7, and dopamine D2-long and D3 receptors).

2 tent and competitive antagonist at the human D3 receptor.

3 ffinities at the sub-nanomolar level for the D3 receptor.

4 ated by the D1 receptor and inhibited by the D3 receptor.

5 ly mediated by the prominence of dopamine D2/D3 receptors.

6 riatum and excessive stimulation of dopamine D3 receptors.

7 d in CHO cells expressing either human D2 or D3 receptors.

8 n our hybrid molecular template targeting D2/D3 receptors.

9 receptors and AtT-20 cells expressing human D3 receptors.

10 molecules developed earlier for dopamine D2/D3 receptors.

11 receptors and AtT-20 cells expressing human D3 receptors.

12 affinity at 5HT1A, 5HT1B, 5HT1C, D1, D2, or D3 receptors.

13 ounds with high affinity and selectivity for D3 receptors.

14 d for high-affinity and selective binding to D3 receptors.

15 arkedly different cellular distribution than D3 receptors.

16 r (PAM) of the rat and human dopamine D2 and D3 receptors.

17 tiate [(3)H]-dopamine binding at both D2 and D3 receptors.

18 se disorder reverses deficits in striatal D2/D3 receptors.

19 ; D2 = 3.23 and D3 = 1.41 nM) at both D2 and D3 receptors.

20 values were determined for D(2L), D(2S), and D3 receptors.

21 and evaluated as ligands for the dopamine 3 (D3) receptor.

22 opamine synthesis ([(18)F]DOPA), dopamine D2/D3 receptors ([(11)C]raclopride), and serotonin transpor

23 ir3) channels is strongly implicated because D3 receptors activate channels composed of GIRK2 subunit

24 We then tested whether D3 receptors activate GIRK currents in SN dopamine neuro

25 motor cortex that differs from predominantly D3 receptor activation and that the kind of plasticity-i

26 D3 receptor activation differentially affected dopamine

27 eceptor functions, we examined the effect of D3 receptor activation on GABAA receptor (GABAAR)-mediat

28 vesicle trafficking dye FM1-43, we show that D3 receptor activation significantly inhibits spontaneou

29 Together, our results suggest that D3 receptor activation suppresses the efficacy of inhibi

30 Within these neurons, D3 receptor activation was found to regulate low-voltage

31 different properties with respect to vitamin D3 receptor activation, anti-inflammatory activity, and

32 e products were compared in terms of vitamin D3 receptor activation, anti-inflammatory, and antiproli

33 n homo-oligomers and are consistent with the D3 receptor adopting a beta1-adrenoreceptor-like quatern

34 to have a major influence on (sub)nanomolar D3 receptor affinity and D2/D3 selectivity, which was op

35 class of compounds with the goal to improve D3 receptor affinity and selectivity.

36 are also oppositely regulated by the D1 and D3 receptors after repeated exposure to cocaine.

37 ent study, we developed the (18)F-labeled D2/D3 receptor agonist (R)-(-)-2-(18)F-fluoroethoxy-N-n-pro

38 enic, and behavioral effects of the dopamine D3 receptor agonist 7-OH-DPAT (7-hydroxy-N,N-di-n-propyl

39 Furthermore, a D3 receptor agonist increased choice of the disadvantage

40 We conclude that a dopamine D3 receptor agonist preferentially affects brain activit

41 e systemic administration of the dopamine D2/D3 receptor agonist quinpirole (0.05 mg/kg).

42 and the anti-parkinsonian effects of the D2/D3 receptor agonist ropinirole.

43 h the D3 receptor antagonist, U99194, or the D3 receptor agonist, 7-OH-DPAT, did not alter choice beh

44 -1, 4-oxazin-9-ol hydrochloride], a specific D3 receptor agonist, caused a significant reduction of G

45 Quinpirole, a D2/D3 receptor agonist, had no effect on evoked dopamine re

46 plasticity, and the D2/D3, but predominantly D3, receptor agonist ropinirol has a dosage-dependent no

47 Like low dopamine, the D3 receptor agonists pergolide and PD 128907 reduced MSR

48 species, the results are consistent with the D3 receptor also assuming a quaternary structure in whic

49 r the inhibition of Akt by dopamine and that D3 receptors also participate in this signaling potentia

50 genetic manipulations that affect prefrontal D3 receptors alter anxiety, social interaction, and reve

51 organization and potential stability of the D3 receptor and possibly other GPCR quaternary structure

52 ormed to quantify binding availability of D2/D3 receptors and dopamine transporters (DATs).

53 The disruption of the coupling between D2/D3 receptors and Galphai2 by AMPH is at least partially

54 of the third intracellular domain of D2 and D3 receptors and the carboxyl-terminal domain of protein

55 nverse relationship between dopamine (DA) D2/D3 receptors and vulnerability to cocaine abuse, althoug

56 ction with FLN-A was specific for the D2 and D3 receptors and was independently confirmed in pull-dow

57 3) and MC1288 (4), which bind to the vitamin D3 receptor, and R04 (5), an inhibitor bound to human rh

58 acebo or a single low dose (50 mg) of the D2/D3 receptor antagonist amisulpride, which is believed to

59 acebo or a single low dose (50 mg) of the D2/D3 receptor antagonist amisulpride, which is believed to

60 is hypothesis, we examined the effect of the D3 receptor antagonist nafadotride on sensitization.

61 In contrast, the dopamine D2/D3 receptor antagonist raclopride reduced the seeking of

62 kedly attenuated by infusion of the dopamine D3 receptor antagonist SB-277011-A into the amygdala (2

63 perties of cocaine, the potent and selective D3 receptor antagonist trans-N-[4-[2-(6-cyano-1,2,3,4-te

64 amined the influence of U-99194A, a dopamine D3 receptor antagonist, on ethanol's rewarding effect in

65 Treatment with the D3 receptor antagonist, U99194, or the D3 receptor agoni

66 Conversely, D3 receptor antagonists (GR 103691 and nafadotride) incr

67 Dopamine D3 receptor antagonists and partial agonists have been s

68 ort a class of potent and selective dopamine D3 receptor antagonists based upon tranylcypromine.

69 y depended on dopamine, because giving D1/D2/D3 receptor antagonists reduced these behaviors, but als

70 eased by systemic administration of dopamine D3 receptor antagonists.

71 Moreover, the D1 and D3 receptors are also coexpressed in the same neurons, p

72 nd FLAG-tagged D3 receptors, suggesting that D3 receptors are capable of forming homodimers.

73 dopamine transporters (DATs) and dopamine D2/D3 receptors are implicated in a variety of neurological

74 Agonists at dopamine D2 and D3 receptors are important therapeutic agents in the tre

75 Our data suggest that midbrain D2/D3 receptors are more susceptible to AMPH-induced altera

76 nts had reduced 11C-raclopride binding to D2/D3 receptors at rest in the bilateral striatum, consiste

77 ion and reduced 11C-raclopride binding to D2/D3 receptors at rest was seen.

78 gion of reduced 11C-raclopride binding to D2/D3 receptors at rest.

79 in 58 methamphetamine users) and dopamine D2/D3 receptor availability (binding potential relative to

80 paminergic genes associated with dopamine D2/D3 receptor availability (D2R), no study to date has inv

81 f significant case-control differences in D2/D3 receptor availability (despite the observed relations

82 suggests that exercise increases striatal D2/D3 receptor availability (measured as nondisplaceable bi

83 n that sleep deprivation reduced dopamine D2/D3 receptor availability (measured with PET and [(11)C]r

84 es of growth, nor did it influence DAT or D2/D3 receptor availability after 1 year of treatment.

85 cial group have significant elevations in D2/D3 receptor availability and are less vulnerable to coca

86 and limbic networks, they had equivalent D2/D3 receptor availability and equivalent increases in end

87 elease occuring in the setting of reduced D2/D3 receptor availability and raise the possibility that

88 The relationship between D2/D3 receptor availability and vulnerability to cocaine re

89 ssociated with baseline striatal dopamine D2/D3 receptor availability and with methylphenidate-induce

90 methylphenidate (measured as decreases in D2/D3 receptor availability compared with placebo) did not

91 With the placebo, D2/D3 receptor availability in left caudate was lower (P <

92 quantify individual differences in putative D3 receptor availability in rodents trained on a novel t

93 Neither DAT nor D2/D3 receptor availability in the caudate nucleus and puta

94 We corroborated a decrease in D2/D3 receptor availability in the ventral striatum with sl

95 However, after washout, the D2/D3 receptor availability of MPH-treated animals did not

96 DA D2/D3 receptor availability significantly increased in fema

97 DA D2/D3 receptor availability was assessed in female cynomolg

98 We observed decreases in D2/D3 receptor availability with age, while presynaptic ves

99 ing with striatal regions showing reduced D2/D3 receptor availability, except for a cluster in the le

100 system possibly due to decreased striatal D2/D3 receptor availability.

101 nd [11C]raclopride (RAC), an indicator of D2/D3 receptor availability.

102 eport computational homology modeling of the D3 receptor based upon the high-resolution X-ray structu

103 levels (using microdialysis) and dopamine D2/D3 receptor binding (using positron emission tomography)

104 Several analogues demonstrated superior D3 receptor binding affinities and selectivities as comp

105 ophilicity (c log D = 6.94) while optimizing D3 receptor binding affinity and D2/D3 selectivity.

106 of 20 compounds selected for testing in the D3 receptor binding assay.

107 Increased dopamine D2/D3 receptor binding in the anteroventral striatum has be

108 24 appears suitable for quantification of D2/D3 receptor binding in vivo, and the results encourage e

109 We tested the hypothesis that D3 receptor binding is above normal in methamphetamine (

110 describes the binding of ligands at a single D3 receptor binding site and offers insights into the bi

111 DA D2/D3 receptor binding was altered both in mice and in huma

112 1)C]raclopride competes with dopamine for D2/D3 receptor binding) or receptor downregulation.

113 was correlated with striatal but not OFC D2/D3 receptor binding.

114 nucleus and a corresponding reduction in D2/D3 receptor binding.

115 Thus, D3 receptor blockade attenuates both the rewarding effec

116 response to ethanol and further suggest that D3 receptor blockade increases ethanol reward.

117 w that we have identified PAMs of the D2 and D3 receptors both in vitro and in vivo.

118 s of the 8-week interventions on striatal D2/D3 receptor BPND.

119 acer, [(11)C]raclopride, for the dopamine D2/D3 receptor by carbonylation with excellent radiochemica

120 assay in which binding to and activation of D3 receptors by [(3)H]dopamine was prevented.

121 t with HEK-293 cells expressing either D2 or D3 receptors by using tritiated spiperone as radioligand

122 lts not only support the hypothesis that the D3 receptor can regulate secretory activity but also pro

123 introduced into the stable cell line either D3 receptors carrying an hemagglutinin (HA) epitope tag,

124 Of particular interest, dopamine D3 receptors contribute to the beneficial influence of d

125 The dopamine D1 receptor-D3 receptor (D1R-D3R) heteromer is being considered as a

126 dies on the dopamine system have used D2 and D3 receptor (D2/D3) antagonists such as (11)C-raclopride

127 ressed the role of striatal dopamine (DA) D2/D3 receptor (D2/D3R) function in chronic non-neuropathic

128 We investigated whether striatal dopamine D2/D3 receptor (D2R) binding assessed by (123)I-iodobenzami

129 d analogues of sumanirole (1), a dopamine D2/D3 receptor (D2R/D3R) agonist, were synthesized.

130 her alone or in combination with FLAG-tagged D3 receptors, D3nf exhibited a punctate perinuclear dist

131 A series of potent and selective D3 receptor (D3R) analogues with diazaspiro alkane cores

132 4-116, a novel and highly selective dopamine D3 receptor (D3R) antagonist, for the prevention and tre

133 e has inspired investigation of the dopamine D3 receptor (D3R) as a target for therapeutic interventi

134 The dopamine D3 receptor (D3R) has an anatomic distribution that sugg

135 The dopamine D3 receptor (D3R) has been implicated in substance abuse

136 Subtype-selective agents for the dopamine D3 receptor (D3R) have been considered as potential medi

137 d partial agonist modulators of the dopamine D3 receptor (D3R) have emerged as promising therapeutics

138 The crystal structure of the human dopamine D3 receptor (D3R) in complex with the small molecule D2R

139 The dopamine D3 receptor (D3R) is a molecular target for both first-g

140 The dopamine D3 receptor (D3R) is a promising target for the developm

141 The dopamine D3 receptor (D3R) is a target for developing medications

142 The dopamine D3 receptor (D3R) is crucial in the regulation of blood

143 ffinity and selectivity at the dopamine (DA) D3 receptor (D3R) is described.

144 The dopaminergic D3 receptor (D3R) is emerging as an antagonist of sensit

145 Preclinical studies show that the dopamine D3 receptor (D3R) is involved in the reinstatement of dr

146 Both dopamine D3 receptor (D3R) partial agonists and antagonists have

147 ive allosteric ligands of the human dopamine D3 receptor (D3R) using two optimized crystal-structure-

148 binding of a novel APD and DA to a dopamine D3 receptor (D3R) was investigated by looking at electro

149 eased dorsal striatal levels of the dopamine D3 receptor (D3R), a gene downstream of BDNF, via activa

150 t and long isoform variants (D2SR and D2LR), D3 receptor (D3R), and D4 receptor (D4R), with several p

151 hese effects were dependent on functional DA D3 receptor (D3R), because nicotine was inactive both in

152 The structural similarities between dopamine D3 receptor (D3R)-selective molecules that display bitop

153 rd intracellular loop of the limbic dopamine D3 receptor (D3R).

154 tamine required functionally intact dopamine D3 receptors (D3R), as its effects were abolished by sel

155 ing ligands that bind both D2Rs and dopamine D3 receptors (D3Rs), questioning the role of D3Rs in the

156 exercise training can ameliorate striatal D2/D3 receptor deficits in methamphetamine users, and warra

157 Here, we show that D3 receptors define a unique population of glutamatergic

158 Striatal dopamine (DA) D3 receptor density (measured by quantitative receptor a

159 In symptomatic cats, D3 receptor density was significantly decreased in all r

160 eeking by conditioned reinforcers depends on D3 receptor-dependent dopamine transmission in the amygd

161 y a negative allosteric modulator of D2- and D3-receptor dimers, thus identifying the first allosteri

162 and its major metabolite, which had dopamine D3 receptor dissociation constant K (d) values of 320 an

163 d H- (nine repeats)] on striatal dopamine D2/D3 receptor (DRD2) availability and on dopamine release

164 mal studies support the role of the dopamine D3 receptor (DRD3) in alcohol reinforcement or liking.

165 ch a dysfunctional signaling of the dopamine D3 receptor (Drd3) is hypothesized.

166 cules with preferential agonist activity for D3 receptor (EC(50) (GTP gamma S); D3 = 0.52 nM; D2/D3 (

167 )-19b as two potent agonists for both D2 and D3 receptors (EC(50) (GTPgammaS); D2 = 4.51 and 1.69 nM

168 These results suggest that the D1 and D3 receptors elicit opposite regulation of target gene e

169 ressed in HEK 293 cells, FLAG- and HA-tagged D3 receptors exhibited a similar plasma membrane distrib

170 terized for their binding to dopamine D2 and D3 receptors expressed in HEK-293 cells.

171 D3-receptor-expressing neurons send axonal projections t

172 D3-receptor-expressing pyramidal neurons are electrophys

173 ncation fragment reduces the level of D2 and D3 receptor expression at the plasma membrane.

174 chniques, and electrophysiology to show that D3 receptor expression defines a novel subclass of layer

175 These alterations in D3 receptor expression may play an important role in the

176 euroanatomical remodeling of regions rich in D3 receptor expression, and typically altered in schizop

177 evelopment of highly selective compounds for D3 receptor (for (-)-40K(i), D3 = 1.84 nM, D2/D3 = 583.2

178 appears to result in the mislocalization of D3 receptors from the plasma membrane to an intracellula

179 needed to establish whether normalization of D3 receptor function could reduce vulnerability to relap

180 the potential cellular mechanism underlying D3 receptor functions, we examined the effect of D3 rece

181 addition, a Ser9Gly variant in the dopamine D3 receptor gene on 3q13 has been suggested to be a risk

182 like lead compounds with selectivity for the D3 receptor has been challenging because of the high seq

183 Pharmacological activation of the dopamine D3 receptor has been shown to trigger neurogenesis in th

184 A physiological role for the D3 receptor has not been identified, but an activation o

185 oncentrations of dopamine transporter and D2/D3 receptors have been observed in the amygdaloid comple

186 Both the dopamine D1 and D3 receptors have been shown to mediate gene expression

187 To study the involvement of the D3 receptor in brain mechanisms and behaviors commonly a

188 mputational approach implicates the dopamine D3 receptor in decision-making processes that are altere

189 However, the role of D3 receptors in adaptive, goal-directed behavior has not

190 ng results indicated highest selectivity for D3 receptors in compound (-)- 10 ( K i = 0.35 nM; D2/D3

191 , thus identifying a unique role of midbrain D3 receptors in decision-making processes.

192 ant tool with which to elucidate the role of D3 receptors in drug reinforcement in vivo.

193 f reduced FAAH function with higher dopamine D3 receptors in human and mouse brain provide a mechanis

194 These data suggest an important role for D3 receptors in mediating the addictive properties of co

195 ngs are consistent with the reported role of D3 receptors in mediating the facilitatory effects of cu

196 ing novel circuitry and cellular actions for D3 receptors in PFC.SIGNIFICANCE STATEMENT The D3 dopami

197 ne unique circuitry and cellular actions for D3 receptors in regulating PFC networks.

198 monstrate a previously unrecognized role for D3 receptors in select aspects of reinforcement learning

199 ndings provide novel insights on the role of D3 receptors in structural changes observed following AP

200 nist radioligand for imaging dopamine D2 and D3 receptors in the human brain with PET.

201 shed the interaction between Galphai2 and D2/D3 receptors in the midbrain while leaving striatal D2/D

202 ts are discussed with respect to the role of D3 receptors in the transport response and the nature of

203 s are consistent with a downregulation of D2/D3 receptors in ventral striatum with sleep deprivation

204 s reduced binding of [(11)C]raclopride to D2/D3 receptors) in detoxified cocaine abusers.

205 uggest that individual variation in midbrain D3 receptors influences flexible behavior.

206 We therefore hypothesized that tolerance of D3 receptor inhibition of locomotion contributes to the

207 the transport response and the nature of D2-D3 receptor interactions.

208 racellular helix VIII in the formation of D3-D3 receptor interfaces within homo-oligomers and are con

209 The dopamine D3 receptor is a class A, rhodopsin-like G protein-coupl

210 cycle in developing and adult brain, and the D3 receptor is known to play an important role in dopami

211 dopamine D3 receptor is preferentially localized to the mesocorti

212 anylcypromine has a low affinity for the rat D3 receptor (K(i) = 12.8 muM), our efforts have yielded

213 nds on spinal reflexes in wild-type (WT) and D3-receptor knock-out mice (D3KO).

214 had lower alpha-synuclein load and dopamine D3 receptor levels in the nucleus accumbens.

215 Downregulation of the dopamine D3 receptor levels may have occurred either as a consequ

216 emented by additional use of 123I-labeled D2/D3 receptor ligand co-injected to assess both pre- and p

217 creases (measured with [11C]raclopride, a D2/D3 receptor ligand with binding that is sensitive to end

218 have advantages over other dopamine (DA) D2/D3 receptor ligands because, as an agonist, it measures

219 task was uniquely sensitive to modulation by D3 receptor ligands, yet these drugs did not alter decis

220 ocaine and suggest that blockade of dopamine D3 receptors may constitute a new and useful target for

221 ed sensitivity of choice on the cued task to D3-receptor-mediated neurotransmission data suggest that

222 a, that dopaminergic activity at the related D3 receptor might, in contrast, be elevated and thereby

223 ans, because physiological effects of D2 and D3 receptors might differ.

224 eptor was modeled computationally using four D3 receptor models which were obtained from homology mod

225 ved FRET, the interfaces that allow dopamine D3 receptor monomers to interact were defined and used t

226 C385A mice confirmed significantly increased D3 receptor mRNA across examined regions (7-44%; p < 0.0

227 In contrast, D3 receptor mRNA expression was slightly elevated in sym

228 ons of newborn mice, effects not observed in D3 receptor null mutant mice mice.

229 gns was related to normalization of striatal D3 receptor number.

230 nding potential (BP) to striatal dopamine D2/D3 receptors on average by 29.2%, which was associated w

231 atin transcription responsive to the vitamin D3 receptor or to Gal4-VP16.

232 ic selectivity, (b) increase the affinity at D3 receptors, or (c) decrease the affinity at D2 recepto

233 nt influence on the regulation of DATs or D2/D3 receptors, or on standard measures of growth.

234 hat are >100-fold selective for the dopamine D3 receptor over dopamine D2 receptor (D2R), despite hig

235 e analogues showed exquisite selectivity for D3 receptors over >60 other receptors, further underscor

236 In the present report, the D3 receptor pharmacophore is modified in the 2,3-diCl- a

237 prove useful in the elucidation of the role D3 receptors play in the psychomotor stimulant and reinf

238 Dopamine D3 receptor positron emission tomography ligands have re

239 s of magnitude was determined for this novel D3-receptor-preferring ligand, compared to 1.

240 Dopamine D2 and dopamine D3 receptors protein levels in the nucleus accumbens, fr

241 e receptors and used this cell line to study D3 receptor-protein interactions.

242 hy and raclopride labeled with carbon 11 (D2/D3 receptor radioligand sensitive to competition with en

243 tomography and [11C]raclopride (dopamine D2/D3 receptor radioligand) and [11C]cocaine (dopamine tran

244 guanfacine with [(11)C]FLB457, a dopamine D2/D3 receptor radiotracer, and positron emission tomograph

245 These results demonstrate that D3 receptors regulate dopamine transporter function and

246 Whether D3 receptors regulate dopamine transporter function is u

247 tion and identify a novel mechanism by which D3 receptors regulate extracellular dopamine concentrati

248 However, the mechanisms by which D3 receptors regulate prefrontal circuits and whether D3

249 ors regulate prefrontal circuits and whether D3 receptors regulate specific prefrontal subnetworks re

250 Within these cells, we find that D3 receptors regulate the ability to generate high-frequ

251 Therefore, these data indicate that D3 receptors regulate the excitability of a unique, IT p

252 2.7 and 2.8 nM at the rat and human dopamine D3 receptors, respectively, and displays respective sele

253 ad K(i) values of 62.8 and 2.4 nM for D2 and D3 receptors, respectively.

254 n (K(i)) values of 1.8 and 0.2 nM for D2 and D3 receptors, respectively.

255 artite information weight matrix for vitamin D3 receptor/retinoid X receptor alpha (VDR/RXRalpha) bin

256 ons have been hampered by the lack of highly D3 receptor selective compounds that can be used in vivo

257 ts of buspirone were similar to those of the D3 receptor-selective antagonist PG01037 and qualitative

258 To address this problem, the potent and D3-receptor-selective antagonist NGB 2904 (1, 9H-fluoren

259 y play a role in both enantioselectivity and D3 receptor selectivity.

260 r smoking increases DA concentrations at the D3 receptor, speculated to have a role in nicotine's add

261 epitope tag, or an HA-tagged version of the D3 receptor splice variant D3nf.

262 D3 receptor stimulation activated phosphoinositide 3-kin

263 The dopamine D3 receptor subtype has been recently targeted as a pote

264 Dopamine D3 receptor subtypes have been hypothesized to play a pi

265 clues for the diversity in SAR at the D2 and D3 receptor subtypes.

266 ridol or genetic ablation of dopamine D2 and D3 receptors, suggesting that blockade of D2-like signal

267 we coimmunoprecipitated HA- and FLAG-tagged D3 receptors, suggesting that D3 receptors are capable o

268 se responses were accompanied by dopamine D2/D3 receptor supersensitivity.

269 ful in determining how intrinsic activity at D3 receptors tested in vitro is related to behaviors in

270 nearly 5 times more potent antagonist at the D3 receptor than 1 (EC50 = 14.4 nM).

271 Recent studies using ligands for the vitamin D3 receptor, the peroxisome proliferator-activated recep

272 8) exhibited the highest affinity for D2 and D3 receptors, the (-)-isomer being the eutomer.

273 cells co-expressing dopamine transporter and D3 receptors, the D2/D3 agonist quinpirole produced a ra

274 We propose a functional model in which the D3 receptor tightly regulates neurotransmitter release a

275 s, and the weak and inconsistent coupling of D3 receptors to classical signal transduction pathways.

276 Thus, low dopamine activates D3 receptors to limit reflex excitability.

277 stimulation of mitogenesis at human dopamine D3 receptors transfected into Chinese hamster ovary (CHO

278 rs in the midbrain while leaving striatal D2/D3 receptors unchanged.

279 drug wanting." We conclude that the dopamine D3 receptor, unlike the D2 receptor, might be upregulate

280 ompounds were determined for dopamine D2 and D3 receptors using radioligand binding techniques.

281 ted that retinoic acid (RAR-RXR) and vitamin D3 receptors (VDR-RXR) heterodimers recruit only one coa

282 nt study, binding of 29 known ligands to the D3 receptor was modeled computationally using four D3 re

283 he 5-hydroxy series, highest selectivity for D3 receptors was exhibited by compound (-)- 25 ( K i = 0

284 activation, which may impact on both D2 and D3 receptors, was exclusively associated with variations

285 s with endogenous dopamine for binding to D2/D3 receptors, we interpret the decreases in binding to r

286 D2 and D3 receptors were also found to interact with the highly

287 lly coupled to Galphai2, whereas striatal D2/D3 receptors were coupled equally to Galphai2 and Galpha

288 highest binding affinity and selectivity for D3 receptors were exhibited by (-)-34 (Ki=0.92 nM and D2

289 of choice behavior, while drugs that act on D3 receptors were ineffective.

290 ced into the stable D3-expressing cell line, D3 receptors were no longer visualized at the plasma mem

291 nstrated for the first time that midbrain D2/D3 receptors were preferentially coupled to Galphai2, wh

292 asures high-affinity, functionally active D2/D3 receptors, whereas the traditionally used radiotracer

293 The dopamine D3 receptor, which is highly enriched in nucleus accumbe

294 y relationships for this class of ligands at D3 receptors will provide new leads toward the developme

295 agonist activity with picomolar affinity for D3 receptor with high selectivity (EC50=0.08 nM and D2/D

296 at this compound is a partial agonist at the D3 receptor with no detectable activity at the D2 recept

297 t with HEK-293 cells expressing either D2 or D3 receptor with tritiated spiperone to evaluate inhibit

298 However, expression of D2 or D3 receptors with a protein 4.1N truncation fragment red

299 t with HEK-293 cells expressing either D2 or D3 receptors with tritiated spiperone to evaluate inhibi

300 t with HEK-293 cells expressing either D2 or D3 receptors with tritiated spiperone to evaluate inhibi